Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers […]
New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]
Collaboration with National Institutes of Health and Binghamton University to Develop Novel Antibody-Drug Conjugates for Pediatric Cancer https://www.issuewire.com/manhattan-biosolutions-enters-into-collaboration-agreements-with-the-nih-and-binghamton-university-to-develop-novel-adc-1781455477718844 New York City, New […]